FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
about
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.New horizons in tumor microenvironment biology: challenges and opportunitiesTranslational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinomaInsulin growth factor 1 like receptor (IGF-1R).Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancerGlobal transcriptome and sequenome analysis of formalin-fixed salivary epithelial-myoepithelial carcinoma specimensThe mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patientsFGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer.The role of TWIST1 in epithelial-mesenchymal transition and cancers.MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cellsNeratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.Advances and challenges in targeting FGFR signalling in cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.Production of bFGF monoclonal antibody and its inhibition of metastasis in Lewis lung carcinoma.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cellsPersonalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
P2860
Q27853292-A7363D1F-7CED-44B1-AAA8-AEBA6D533C06Q34704781-B2394F75-077E-42F5-A217-A7ADBEDE709BQ35151324-DD115764-30AC-4E92-BB50-2543659A9886Q35219539-2868FDA3-6E51-433B-8AE3-AC64CCD0D887Q35781614-AEE4F7FD-264F-43AA-ADBA-6BBD1E7E899BQ36157136-FF089D79-3786-482D-9CAC-F203423BC550Q36238664-3F98530C-A655-4F31-B70F-DFCA3143F4E3Q36298492-2547133C-CD12-45D9-9BEF-4BCA6FF048D8Q36306149-738FFFFE-604F-438C-8806-E36FACD7EC27Q36838327-F4853CDB-2BF2-49E6-9913-6F3C195CE236Q37022191-455F2F0B-C29F-457B-83D6-9BCA17B982C3Q37696325-FC4DB8B4-C5D2-472D-B947-8B3AC188FEF0Q37699384-F94DCE96-7A4E-4E16-BCF5-12906F8B89A9Q38646345-A54AFDEC-1815-461D-9ADD-EA80AA79FF57Q38709287-0C6BC539-8671-4AAF-8A3C-AAE17E342524Q38718320-931D062B-176E-4D49-9FB8-727443F0F845Q39131033-9462017B-98A1-4C55-AFB1-047C2FF2638AQ39183442-756F8430-6C70-455D-808E-8BC5B835443EQ39226762-202A1828-58F4-485A-AA22-113C4F207C7EQ41472694-E296779A-9744-4303-93F6-DA7456C5273DQ41561392-B479BBC9-FDDB-47DA-A64A-E28DC8DFF661Q42378470-71D19F2C-7913-49B0-AE03-DDE86F9AC6E8Q42658363-66A75CA0-57D2-46C8-832E-49BB56B4F277Q47146662-C2A01F0D-4DBA-43D0-A3A0-004356486E80Q49959280-598D9BF7-C408-4FE9-BAE0-216C016AC680Q52589214-709D6AE2-24E8-49F7-9E0F-F3EE6B4AD062Q52661758-DF6894DF-9FBF-4547-8B8B-01693530295EQ54964630-40A29A28-D0FE-4547-AFED-8BD221CC9379Q55025386-9CB026FB-982D-46EA-A226-60C46CC5A13CQ55998133-3D0A6214-76C5-468F-BC40-1F85DBED6DD3Q57177486-DE3C1B8A-1C8B-44E2-88D1-D0718C829CAB
P2860
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
FGFR1 activation is an escape ...... -EGFR family kinase inhibitor.
@en
type
label
FGFR1 activation is an escape ...... -EGFR family kinase inhibitor.
@en
prefLabel
FGFR1 activation is an escape ...... -EGFR family kinase inhibitor.
@en
P2093
P2860
P356
P1433
P1476
FGFR1 activation is an escape ...... -EGFR family kinase inhibitor.
@en
P2093
Akihiko Kawahara
Hiroto Izumi
Kahori Sonoda
Kazutaka Nakashima
Koichi Azuma
Kosuke Watari
Kousuke Tashiro
Masayoshi Kage
Mayumi Ono
Michihiko Kuwano
P2860
P304
P356
10.18632/ONCOTARGET.1866
P407
P577
2014-08-01T00:00:00Z